Table 1

Serious infections, comparison between different bDMARDs/tsDMARDs (observational studies)

Study IDRegistryInterventionControlaHR (I vs C)Risk of bias
Serious infections
Carrara 2019
Clin Exp Rheumatol11
RECORDADAETA1.4 (1.0; 2.0)High
IFX1.0 (0.6; 1.6)
CZP1.3 (0.5; 3.6)
GOL1.1 (0.4; 3.2)
ABA 0.3 (0.1; 0.8)
RTX1.0 (0.5; 1.9)
TCZ1.2 (0.6; 2.6)
Cecconi 2018
J Clin Rheumatol12
BIOBADABRASILADAIFX aIRR: 0.5 (0.4; 0.8)Moderate
ETAaIRR: 0.8 (0.6; 1.2)
Grøn 2019
Ann Rheum Dis15
DANBIO and ARTISABARTXaIRR: 0.9 (0.7; 1.1)Low
TCZaIRR: 0.8 (0.6; 1.0)
Harrold 2018
Arthritis Res Ther16
CORRONACZPOther TNFiaIRR: 1.3 (0.8; 1.9)Low
Machado 2018
Arthritis Res Ther18
Claims databaseTNFiNon-TNFi1.1 (1.0; 1.4)High
TOFA1.5 (0.9; 2.6)
Mori 2017
PLoS One19
SARABAIFXETA1.5 (0.8; 3.0)Moderate
ADA1.7 (0.9; 3.3)
ABA1.1 (0.6; 2.2)
TCZ1.0 (0.6; 1.9)
Pawar 2019
Ann Rheum Dis20
Claims databaseTCZTNFi1.1 (1.0; 1.2)High
ABA1.4 (1.2; 1.6)
Rutherford 2018
Ann Rheum Dis23
BSRBR-RAIFXETA0.9 (0.8; 1.0)Low
ADA1.0 (0.9; 1.1)
RTX0.9 (0.8; 1.0)
TCZ 1.2 (1.0; 1.5)
CZP 0.8 (0.6; 1.0)
Silva-Fernández 2018
Rheumatology (Oxford)24
BSRBR-RARTXTNFi1.0 (0.7; 1.4)Low
Opportunistic infections
Pawar 2019
Ann Rheum Dis20
Claims databaseTCZTNFi1.0 (0.6; 1.8)High
ABANR
Rutherford 2018
Rheumatology (Oxford)22
BSRBR-RARTXTNFi1.0 (0.6; 1.5)Low
TCZ0.5 (0.2; 1.7)
Herpes zoster
Pawar 2019
Ann Rheum Dis20
Claims databaseTCZTNFi0.9 (0.5; 1.7)High
ABANR
Curtis 2016
Ann Rheum Dis14
Claims databaseADAABA1.0 (0.8; 1.3)High
CZP1.1 (0.9; 1.5)
ETA1.1 (0.9; 1.3)
GOL1.1 (0.8; 1.6)
IFX1.2 (1.0; 1.4)
RTX1.1 (0.9; 1.4)
TCZ1.1 (0.9; 1.4)
TOFA 2.0 (1.4; 2.9)
Tuberculosis
Cho 2017
Semin Arthritis Rheum13
Claims databaseMonoclonal AB (ADA; GOL; IFX)ETA aOR: 2.5 (1.5; 4.3)High
Lim 2017
Plos one17
Files from Taichung Veterans General HospitalADAETA aIRR: 1.9 (1.3; 2.7)* High
GOL
TCZ
ABA
TOFA
Pawar 2019
Ann Rheum Dis20
Claims databaseTCZTNFiHigh
ABANR
Rutherford 2018
Rheumatology (Oxford)22
BSRBR-RARTXTNFi 0.2 (0.0; 0.7)Low
TCZ0.4 (0.1; 2.6)
Pneumocystis jirovecii pneumonia
Rutherford 2018
Rheumatology (Oxford)22
BSRBR-RARTXTNFi 3.2 (1.4; 7.5)Low
TCZNR
  • *Including only patients without history of tuberculosis (effect not significant if including all patients irrespective of history).

  • †No cases of tuberculosis occurred so comparisons are not possible. Values in bold reflect a statistically significantly effect (ie, ratio different from 1). Additional details in online supplementary tables S2–31

  • ABA, abatacept; ADA, adalimumab; aHR, adjusted HR; aIRR, adjusted incidence rate ratio; aOR, adjusted OR; ARSTIS, anti-Rheumatic Treatment in Sweden Register; bDMARDs, biologic disease-modifying antirheumatic drugs; BSRBR, British Society of Rheumatology Biologics Register; CORRONA, Consortium of Rheumatology Researchers of North America; CZP, certolizumab pegol; ETA, etanercept; GOL, golimumab; IFX, infliximab; NR, not reported; RA, rheumatoid arthritis; RECORD, RECord-linkage On Rheumatic Diseases (administrative dataset); RTX, rituximab; TCZ, tocilizumab; TNFi, tumour necrosis factor inhibitor; TOFA, tofacitinib; tsDMARD, target synthetic disease-modifying antirheumatic drugs.